Back to Newsroom

PTC Completes Enrollment of Phase 3 Clinical Trial of Translarna™ for Patients with Cystic Fibrosis

SOUTH PLAINFIELD, N.J., Nov. 19,  2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has completed enrollment of ACT CF, the company’s second Phase 3 clinical trial of Translarna™ (ataluren) for patients with nonsense mutation cystic fibrosis (nmCF). Nonsense mutations in cystic fibrosis are categorized as Class I mutations, which are the most difficult to treat, as they result in little or no production of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Approximately 10 percent of cystic fibrosis patients have their disease as a result of a nonsense mutation.

Click here to read more